JP2006512398A - 膀胱上皮内へのウイルスの形質導入の増強のための方法および試薬 - Google Patents

膀胱上皮内へのウイルスの形質導入の増強のための方法および試薬 Download PDF

Info

Publication number
JP2006512398A
JP2006512398A JP2004565744A JP2004565744A JP2006512398A JP 2006512398 A JP2006512398 A JP 2006512398A JP 2004565744 A JP2004565744 A JP 2004565744A JP 2004565744 A JP2004565744 A JP 2004565744A JP 2006512398 A JP2006512398 A JP 2006512398A
Authority
JP
Japan
Prior art keywords
bladder
composition
pretreatment
luminal surface
transduction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004565744A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006512398A5 (https=
Inventor
ラメシュ，ナガラハン
フレイ，デヴィッド
メマーザデー，バーラム
ユー，デチャオ
Original Assignee
セル ジェネシス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セル ジェネシス，インコーポレーテッド filed Critical セル ジェネシス，インコーポレーテッド
Publication of JP2006512398A publication Critical patent/JP2006512398A/ja
Publication of JP2006512398A5 publication Critical patent/JP2006512398A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
JP2004565744A 2002-12-26 2003-12-24 膀胱上皮内へのウイルスの形質導入の増強のための方法および試薬 Withdrawn JP2006512398A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/327,869 US7459154B2 (en) 2002-12-26 2002-12-26 Methods and reagents for the enhancement of virus transduction in the bladder epithelium
PCT/US2003/041379 WO2004060303A2 (en) 2002-12-26 2003-12-24 Methods and reagents for the enhancement of virus transduction in the bladder epithelium

Publications (2)

Publication Number Publication Date
JP2006512398A true JP2006512398A (ja) 2006-04-13
JP2006512398A5 JP2006512398A5 (https=) 2007-02-15

Family

ID=32680762

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004565744A Withdrawn JP2006512398A (ja) 2002-12-26 2003-12-24 膀胱上皮内へのウイルスの形質導入の増強のための方法および試薬

Country Status (9)

Country Link
US (7) US7459154B2 (https=)
EP (1) EP1583502A4 (https=)
JP (1) JP2006512398A (https=)
KR (1) KR20050088231A (https=)
CN (1) CN1753618A (https=)
AU (1) AU2003299972C1 (https=)
CA (1) CA2510903A1 (https=)
NZ (1) NZ540732A (https=)
WO (1) WO2004060303A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013516978A (ja) * 2010-01-12 2013-05-16 バスキュラー バイオジェニックス リミテッド アデノウイルスベクターの生産方法およびそれによって生成されるウイルス調製物
JP2023532544A (ja) * 2020-07-01 2023-07-28 メディミューン，エルエルシー 生物学的製剤を精製するための洗浄剤及び方法

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7459154B2 (en) * 2002-12-26 2008-12-02 Cell Genesys, Inc. Methods and reagents for the enhancement of virus transduction in the bladder epithelium
US20050059613A1 (en) * 2003-07-08 2005-03-17 Bahram Memarzadeh Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium
KR20140002082A (ko) * 2005-01-14 2014-01-07 유리젠, 인코포레이티드 하부 요로 장애 치료용 키트 및 개선된 조성물
US8575333B2 (en) 2006-09-14 2013-11-05 Bahram Memarzadeh Halogenated alkyl di- and trisaccharides, pharmaceutical formulations, diagnostic kits and methods of treatment
EP2296678A4 (en) * 2008-05-27 2012-03-21 Oncolytics Biotech Inc MODULATION OF INTERSTITIAL PRESSURE AND ONCOLYTIC VIRUS RELIEF AND DISTRIBUTION
DE102011085501A1 (de) * 2011-10-31 2013-05-02 Söring GmbH Elektrochirurgievorrichtung
ES2994611T3 (en) * 2015-10-19 2025-01-27 Cg Oncology Inc Methods of treating solid or lymphatic tumors by combination therapy
WO2017156349A1 (en) 2016-03-10 2017-09-14 Cold Genesys, Inc. Methods of treating solid or lymphatic tumors by combination therapy
EP4599893A3 (en) 2017-04-14 2025-11-05 CG Oncology, Inc. Cg0070 for treating bcg resistant bladder carcinoma in situ
CN110393808B (zh) * 2019-01-07 2022-06-03 四川安可康生物医药有限公司 增强系统免疫应答的免疫溶瘤病毒组合药物及其应用
CN113717953B (zh) * 2021-08-05 2024-07-26 北京舜雷科技有限公司 一种减毒黄病属病毒在溶瘤中的应用
WO2025251009A1 (en) * 2024-05-31 2025-12-04 Cg Oncology, Inc. Methods of treating bladder cancer using an oncolytic virus and a transduction-enhancing agent

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US169138A (en) * 1875-10-26 Improvement in folding lounges
JPH01245159A (ja) * 1988-03-28 1989-09-29 Gen Corp:Kk ニューカッスル病ウィルス抗体の検出用プレート及び抗原ウィルスの可溶化方法
US5369095A (en) 1990-02-14 1994-11-29 Alcon Laboratories, Inc. Compositions and method comprising substituted glycosides as mucus membrane permeation enhancers
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
US5525519A (en) * 1992-01-07 1996-06-11 Middlesex Sciences, Inc. Method for isolating biomolecules from a biological sample with linear polymers
US5368844A (en) 1992-12-16 1994-11-29 Colgate Palmolive Company Antiplaque, antigingivitis, anticaries oral composition
ES2162115T3 (es) * 1995-12-08 2001-12-16 Kao Corp Composicion germicida.
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US20020169138A1 (en) * 1997-10-24 2002-11-14 Southern Research Institute Delivery vehicles for bioactive agents and uses thereof
US6855549B1 (en) * 1998-11-23 2005-02-15 The University Of Iowa Research Foundation Methods and compositions for increasing the infectivity of gene transfer vectors
US6911200B2 (en) 2000-03-24 2005-06-28 Cell Genesys, Inc. Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation
EP1268761B1 (en) 2000-03-24 2008-12-31 Cell Genesys, Inc. Human urothelial cell specific uroplakin transcriptional regulatory sequences, vectors comprising the same, and methods of use thereof
IL139708A0 (en) * 2000-11-15 2002-02-10 Amiel Gilad Process of decellularizing biological matrices and acellular biological matrices useful in tissue engineering
AUPR894201A0 (en) * 2001-11-19 2001-12-13 Women's And Children's Hospital Respiratory delivery for gene therapy and lentiviral delivery particle
US7459154B2 (en) * 2002-12-26 2008-12-02 Cell Genesys, Inc. Methods and reagents for the enhancement of virus transduction in the bladder epithelium

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013516978A (ja) * 2010-01-12 2013-05-16 バスキュラー バイオジェニックス リミテッド アデノウイルスベクターの生産方法およびそれによって生成されるウイルス調製物
JP2023532544A (ja) * 2020-07-01 2023-07-28 メディミューン，エルエルシー 生物学的製剤を精製するための洗浄剤及び方法

Also Published As

Publication number Publication date
US20080241105A1 (en) 2008-10-02
KR20050088231A (ko) 2005-09-02
US20080112931A1 (en) 2008-05-15
EP1583502A4 (en) 2007-01-17
EP1583502A2 (en) 2005-10-12
US7459154B2 (en) 2008-12-02
WO2004060303A2 (en) 2004-07-22
NZ540732A (en) 2008-01-31
US20090068151A1 (en) 2009-03-12
AU2003299972C1 (en) 2010-12-16
CA2510903A1 (en) 2004-07-22
CN1753618A (zh) 2006-03-29
WO2004060303A3 (en) 2005-11-24
US7267815B2 (en) 2007-09-11
US20080138322A1 (en) 2008-06-12
AU2003299972B2 (en) 2010-05-13
US20040176318A1 (en) 2004-09-09
AU2003299972A1 (en) 2004-07-29
US20040131590A1 (en) 2004-07-08
US20080112932A1 (en) 2008-05-15

Similar Documents

Publication Publication Date Title
US20080138322A1 (en) Methods and reagents for the enhancement of virus transduction in the bladder epithelium
ES2233995T3 (es) Composiciones que contienen un detergente y un gen supresor de tumores, codificado por un vector adenovirico.
Zhang et al. S-RBD-modified and miR-486-5p-engineered exosomes derived from mesenchymal stem cells suppress ferroptosis and alleviate radiation-induced lung injury and long-term pulmonary fibrosis
US20180318307A1 (en) Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases
KR20140146062A (ko) 핵산 전달의 구획화된 방법 및 이의 조성물 및 용도
JP2011148834A (ja) インターフェロン耐性腫瘍の処置のための方法および組成物
WO2004005511A1 (ja) 腫瘍細胞において選択的に増殖する腫瘍融解ウイルス
Wang et al. Construction of exosome-loaded LL-37 and its protection against zika virus infection
Attia et al. Alleviation of pulmonary fibrosis by the dual PPAR agonist saroglitazar and breast milk mesenchymal stem cells via modulating TGFß/SMAD pathway
Bian et al. Tumor-targeted gene transfer in vivo via recombinant Newcastle disease virus modified by a bispecific fusion protein
Kesseli et al. Adeno-associated virus mediates gene transduction after static cold storage treatment in rodent lung transplantation
Sferra et al. Gene transfer to the intestinal tract: a new approach using selective injection of the superior mesenteric artery
Kushwah et al. Potential of helper-dependent adenoviral vectors in modulating airway innate immunity
CN103215234A (zh) 携带锌指核酸酶表达元件和供体dna的腺病毒及其构建方法和应用
US20100113569A1 (en) Isolated dna fragment of the human a33 promoter and its use to control the expression of a heterologous gene in tumor cells
CN111979204B (zh) 携带海绵凝集素基因的溶瘤痘苗病毒、构建方法及用途
Zhang et al. S-RBD-modified and miR-486-5p-engineered exosomes derived from mesenchymal stem cells alleviate radiation-induced lung injury and long-term pulmonary fibrosis via suppression of ferroptosis
Lewis et al. Systemic Senolysis in Naturally Aged Mice Using a FAST-PLV Gene Therapy Approach
Brandon et al. Effect of administration route on biodistribution and shedding of replication-deficient viral vectors used in gene therapy. A literature study
WO2019045049A1 (ja) 腎尿細管細胞特異的発現ベクター
CN102989011A (zh) 一种用于治疗肝癌的药物组合物及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061222

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20090327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090327